Ovarian Cancer
Also known as: Ovary, Ovaries, Ovarian, Fibroid, Leiomyoma
Methodology & AI Transparency ⓘ
Ovarian Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is ovarian cancer? Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor.
- 2 Real-world patient consensus: Mapped to PCOS, Endometriosis & Gynecologic Health under ICD-10-CM C56.9 for Ovarian Cancer clinical workups.
- 3 Typical cash cost range: Clinicians assessing Ovarian Cancer focus on reduced hepatic SHBG in Ovarian Cancer (C56.9: (in PCOS)) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Ovarian Cancer: maintaining CBC & Serum in Ovarian Cancer (C56.9: Ferritin (heavy bleeding)) within Ferritin > 50 ng/mL (C56.9).
Ask our AI Specialists anything about Ovarian Cancer
What Is Ovarian Cancer?
What is ovarian cancer? Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor. Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones . What are the types of ovarian cancer? There are a few different types of ovarian cancer. The most common type is epithelial cancer. It begins in the cells that cover the ovary. There are also two related types of epithelial cancer that can spread to the ovaries: Fallopian tube cancer forms in the tissue lining a fallopian tube.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Ovarian Cancer (C56.9) features reduced hepatic SHBG in Ovarian Cancer (C56.9: (in PCOS)). Cross-referenced with NIH MeSH (Peritoneal Neoplasms, Fallopian Tube Neoplasms), therapeutic stabilization in ob/gyn & pcos is verified against LH, FSH & in Ovarian Cancer (C56.9: Prolactin).
Common Symptoms & Clinical Signs
- • Have a family history of ovarian cancer in a mother, aunt, grandmother, or sister
- • Have inherited changes in the BRCA1 or BRCA2 genes
- • Presentation of Ovarian Cancer (C56.9): hyperandrogenic acne along in Ovarian Cancer (C56.9: the jawline, hirsutism,)
- • Secondary Ovarian Cancer clinical sign: pelvic pressure, bloating, in Ovarian Cancer (C56.9: or pain radiating)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ovarian Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C56.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CBC & Serum in Ovarian Cancer (C56.9: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (C56.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LH, FSH & in Ovarian Cancer (C56.9: Prolactin) | Normal ovulatory endocrine axis (C56.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free & Total in Ovarian Cancer (C56.9: Testosterone + SHBG) | Sex-specific physiological range (C56.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ovarian Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Carboplatin Kyxata • RxCUI 597195 | Platinum-based Drug | 81% | $0.6200 | $ 33.61 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ovarian Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
| New Insights on Reproductive hormone characteristics of obese Chinese patients with polycystic: What a 4,554-Participant Study Found Conversely, they exhibited significantly higher testosterone (T) ( p = 0.001) levels. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2025-12-15 • Meta-Analysis | N = 4,554 | 94/100 | PMID 40287875 ↗ |
| New Insights on Selected side effects during the 12-week induction period of a phase III trial of: What a 690-Participant Study Found Vunakizumab is not significantly associated with the occurrence of any AE or most selected AE categories in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups, whereas vunakizumab is associated... Frontiers in immunology • 2026-01-15 • Phase III Randomized Trial | N = 690 | 93/100 | PMID 42952621 ↗ |
| New Insights on Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women: What a 1,157-Participant Study Found Maintenance therapy with P and PP did not improve OS among patients with newly diagnosed O/tubal/peritoneal cancer, but may modestly increase PFS. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2022-12-10 • Phase III Randomized Trial | N = 1,157 | 90/100 | PMID 35759733 ↗ |
Ovarian Cancer Patient Community & “People Like Me” Threads
Filter Ovarian Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.